Ideally you would think that at where the company has progressed too, the last FDA announcement (amongst other positive Ann) plus a immediate funding runway of one year plus that the sp would have appreciated (despite the dilution).
Value of the IP seemingly continues to be increased, especially with another two years plus of funding (add future options being converted) yet this still fails to reflect in the sp.
That seems to defy logic.
Imo & Imho.
Ann: $35M Capital Raise, page-131
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.25 |
Change
-0.250(1.61%) |
Mkt cap ! $322.3M | |||
| Open | High | Low | Value | Volume |
| $15.50 | $15.50 | $14.80 | $140.4K | 9.315K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 297 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.25 | 1300 | 2 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |